Evidence map›Paper›PMID 41156589›Full record

ArticlePathogens (Basel, Switzerland)2025

A Combination Native Outer Membrane Vesicle (NOVM) Vaccine to Prevent Meningococcal and Gonococcal Disease.

Serena Giuntini, Scarlet W Tefera, Alejandro Bolanos, Adan Ramos Rivera, Gregory R Moe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Serena GiuntiniOMVax, Inc., San Francisco, CA 94111, USA.
Scarlet W TeferaOMVax, Inc., San Francisco, CA 94111, USA.
Alejandro BolanosOMVax, Inc., San Francisco, CA 94111, USA.
Adan Ramos RiveraOMVax, Inc., San Francisco, CA 94111, USA.
Gregory R MoeOMVax, Inc., San Francisco, CA 94111, USA.ORCID 0000-0003-3410-5065

Funding

Novel vaccine strategies for prevention of N. meningitidis group B diseaseR01AI046464 · NIAID · OMVAX, INC. · PI MOE, GREGORY ROBERT · 2000 to 2024
$12.1M
A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groupsR44AI124759 · NIAID · OMVAX, INC. · PI MOE, GREGORY ROBERT · 2020 to 2022
$3.0M
National Institute of Allergy and Infectious Diseases (NIAID) R01AI046464NIAID NIH HHS R01 AI046464NIAID NIH HHS R44 AI124759
6 · The paper itself

Abstract

The increase in the incidence and antibiotic-resistant strains show a need for a broadly protective vaccine to prevent gonorrhea. OMVax has developed a combination vaccine based on native outer membrane vesicles (NOMVs) from two

Indexed as

Bacterial VaccinesGonorrheaMeningococcal InfectionsMeningococcal VaccinesNeisseria gonorrhoeaeNeisseria meningitidisAnimalsAntibodies, BacterialAntigens, BacterialBacterial AdhesionBacterial Outer Membrane ProteinsBacterial ProteinsFemaleHumansMicePorinsAntibodies, BacterialAntigens, BacterialBacterial Outer Membrane ProteinsBacterial ProteinsBacterial VaccinesMeningococcal Vaccinesporin protein, NeisseriaPorinsVaccines, Combinedcarcinoembryonic antigen-related cell adhesion molecule 1colonizationfactor H binding proteinporin outer membrane protein Btransgenic mouse model

Identifiers

PMID41156589
PMCPMC12566994

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.